<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>Dapsone (4,4'-diaminodiphenylsulfone) is employed in the chemotherapy against <z:e sem="disease" ids="C0023343" disease_type="Disease or Syndrome" abbrv="">leprosy</z:e> </plain></SENT>
<SENT sid="1" pm="."><plain>Dapsone also prevents neuronal damage induced by <z:chebi fb="6" ids="14321,29987">glutamate</z:chebi> <z:chebi fb="4" ids="48705">agonists</z:chebi> </plain></SENT>
<SENT sid="2" pm="."><plain>As <z:chebi fb="6" ids="14321,29987">glutamate</z:chebi> excitotoxicity is implicated in the damage after <z:e sem="disease" ids="C0022116" disease_type="Disease or Syndrome" abbrv="">ischemia</z:e>, we tested the ability of dapsone to prevent ischemic injury in a model of permanent middle cerebral artery (<z:chebi fb="70" ids="34342">MCA</z:chebi>) occlusion in rats </plain></SENT>
<SENT sid="3" pm="."><plain>Either dapsone (9.375 or 12.5 mg/kg doses) or vehicle were i.p. administered 30 min after occlusion </plain></SENT>
<SENT sid="4" pm="."><plain>Rats from the control group showed a permanent neurological deficit after occlusion, while dapsone-treated groups improved significantly </plain></SENT>
<SENT sid="5" pm="."><plain>Dapsone-treated animals showed a reduction of 93% (9.375 mg/kg dose) and 92% (12.5 mg/kg dose) in the infarction volume as compared to control values </plain></SENT>
</text></document>